The landscape of drug discovery is undergoing a profound paradigm shift. For decades, the pathology workflow was a linear, terminal process: a tissue sample was collected, stained, examined under a microscope, and then relegated to a storage facility, its scientific utility essentially exhausted. However, the convergence of high-resolution digital imaging, artificial intelligence (AI), and a robust regulatory push to modernize preclinical research is transforming these static archives into vibrant, reusable data assets.
This evolution is not merely a technical upgrade; it represents a fundamental change in how the pharmaceutical industry approaches safety and efficacy. By unlocking the "hidden" data within archived tissue and historical control groups, researchers are discovering that they can answer complex biological questions without the need for additional animal testing.
The Main Facts: Turning Pixels into Progress
Digital pathology, which gained critical momentum during the COVID-19 pandemic as a remote-work necessity, has moved far beyond simple slide viewing. Today, it serves as the backbone of "New Approach Methodologies" (NAMs). Dr. Aleksandra Zuraw, a veterinary pathologist at Charles River Laboratories, encapsulates this shift: "Before, the pathology endpoint was just a report. Now you have the digitized slide, which is pixels."
These pixels represent a goldmine of data. When researchers pair digitized tissue images with existing molecular measurements and study reports, they can train machine learning models to identify subtle patterns linked to molecular changes—patterns that were previously invisible to the human eye.
The primary implication is clear: a glass slide is no longer a one-way street leading to storage. It is now a dynamic data source capable of providing insights into how a drug affects cells and organs long after an experiment has concluded. By leveraging this data, the industry is moving toward a future where the "three Rs"—replacement, reduction, and refinement—are not just ethical goals, but operational standards.
A Chronology of Change: From Microscopes to Machine Learning
The transition toward a digital-first research environment has been characterized by several key milestones that have accelerated the adoption of these technologies.
- Pre-2020: Digital pathology exists as a niche, largely confined to academic research and pilot programs. The glass slide remains the gold standard, and "archived" tissue is viewed as a dormant, logistical burden.
- 2020–2022 (The Pandemic Catalyst): Widespread lockdowns force pathologists to embrace remote sign-outs. Digitization becomes a business continuity necessity, building the infrastructure required for large-scale data storage and cloud-based image analysis.
- December 2022: The U.S. Congress passes the FDA Modernization Act 2.0, a landmark piece of legislation that formally allows for the use of non-animal testing methods in regulatory submissions, provided they are scientifically validated.
- April 2024: Charles River Laboratories launches its "Alternative Methods Advancement Project," signaling a massive institutional commitment to reducing the reliance on traditional animal models.
- April 2025: The FDA releases a comprehensive roadmap for reducing animal testing in preclinical safety studies. The initiative begins with monoclonal antibodies, with a goal to eventually encompass all biologics and chemical entities.
- September 2026: The FDA issues updated regulatory guidance, further codifying the role of NAMs and reinforcing the agency’s commitment to moving away from animal-dependent testing as the default.
Supporting Data: Mining the Archive
The efficacy of this new approach relies on two pillars: the use of "virtual" controls and the molecular analysis of stored tissue blocks.
Virtual Control Groups
In standard toxicology, a significant percentage of animals are used solely as control groups. By establishing a robust database of historical, matched control data, researchers can conduct "virtual" control studies. This practice relies on statistical rigor to ensure that the historical conditions are sufficiently comparable to the current test environment. As Dr. Zuraw notes, the goal is to generate enough high-quality matched data to provide virtual controls wherever possible, effectively cutting the number of animals required for a study by simple arithmetic.
The Power of FFPE Blocks
When tissue is preserved in formalin-fixed, paraffin-embedded (FFPE) blocks, it retains the molecular signatures of its original state. Historically, researchers would need to plan for molecular analysis—such as gene expression or proteomic profiling—before the study began. If a new question arose after the study concluded, a new animal experiment was often required. Today, however, researchers can return to these archived FFPE blocks. By utilizing modern molecular extraction techniques, they can answer new questions about drug mechanisms without needing to start a new trial from scratch.
Official Responses and Regulatory Trajectory
The regulatory environment has shifted from skepticism to active encouragement. The FDA’s push, outlined in their 2025 roadmap, is ambitious. The agency aims to transform the preclinical landscape over the next three to five years, transitioning from a system where animal testing is the requirement to one where NAMs are the default.
This shift is supported by international bodies as well. The Organisation for Economic Co-operation and Development (OECD) published guidance in 2025 specifically addressing the collection and analysis of omics data from preserved tissue. This guidance provides the necessary framework for labs to standardize how they prepare and store samples, ensuring that archived material remains a viable, high-quality resource for future research.
Dr. Zuraw emphasizes that the next phase of this transition will depend on "early adopters." These institutions are currently acting as the pioneers, troubleshooting the technical and regulatory hurdles associated with digital-first workflows. As these pioneers establish successful precedents, the rest of the industry will follow, creating a "snowball effect" in the adoption of these technologies.
Implications: The Future of Drug Discovery
The long-term implications for the pharmaceutical sector are profound.
1. The Death of the "One-Way Street"
The most immediate change is the preservation of the "study context." Because digital slides and archived FFPE blocks are now linked to digitized metadata, researchers can compare new molecular findings with original dosing information and clinical observations. This creates a longitudinal data narrative that was previously lost to the waste bin of history.
2. Emerging Technologies: Virtual Staining
Perhaps the most "cutting-edge" development is the rise of virtual staining. In this scenario, a scanner captures an unstained tissue section, and software generates the appearance of a stain, such as the common hematoxylin and eosin (H&E) stain. By skipping the physical staining process entirely, labs can reduce chemical usage, save time, and potentially improve the reproducibility of the diagnostic process.
3. A Sustainable Research Ecosystem
Ultimately, the integration of these technologies points toward a more sustainable and ethical model for drug discovery. By "extracting more from the same animals, from the same blocks," the industry is reducing its reliance on experimental animals while simultaneously increasing the depth and breadth of the data it generates.
As the industry moves forward, the focus will likely shift toward standardizing the digital platforms required to share this data across institutional boundaries. The goal is no longer just to collect data, but to ensure that the data remains accessible, interoperable, and, most importantly, useful.
In conclusion, the "next act" for digital pathology is not just about technology—it is about intelligence. By treating historical tissue not as waste, but as a living library of biological information, the scientific community is building a more efficient, ethical, and predictive future for medicine. The tools are ready, the regulatory path is clear, and the data is already waiting on the shelves of archives around the world. The only remaining step is to unlock it.
About the Author
